Intermede Investment Partners Ltd lessened its holdings in Danaher Co. (NYSE:DHR – Free Report) by 7.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 576,172 shares of the conglomerate’s stock after selling 45,580 shares during the period. Danaher accounts for approximately 3.5% of Intermede Investment Partners Ltd’s portfolio, making the stock its 10th largest holding. Intermede Investment Partners Ltd’s holdings in Danaher were worth $132,260,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in DHR. FMR LLC raised its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Danaher by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after purchasing an additional 441,012 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares in the last quarter. Fisher Asset Management LLC lifted its position in Danaher by 0.6% during the fourth quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate’s stock valued at $1,051,097,000 after purchasing an additional 26,305 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Danaher by 3.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate’s stock worth $933,524,000 after buying an additional 135,047 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.
Danaher Price Performance
Shares of DHR stock opened at $205.24 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a market cap of $146.69 billion, a P/E ratio of 38.87, a P/E/G ratio of 2.66 and a beta of 0.82. The business’s 50 day moving average price is $221.06 and its 200-day moving average price is $241.48. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70.
Danaher Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio is presently 24.24%.
Insiders Place Their Bets
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.10% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
DHR has been the topic of several research reports. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Guggenheim started coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. The Goldman Sachs Group set a $250.00 price target on shares of Danaher in a research note on Wednesday, January 15th. Jefferies Financial Group cut their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Finally, Scotiabank initiated coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.
View Our Latest Analysis on DHR
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- 10 Best Airline Stocks to Buy
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Growth Stocks: What They Are, What They Are Not
- Why Energy Transfer Belongs on Your Watchlist
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.